The major risk factors for heart disease are the set of measurable biological and behavioral conditions that substantially increase a person’s likelihood of experiencing a heart attack, stroke, or other cardiovascular event. Understanding them matters because risk factors are the bridge between abstract statistics and specific, actionable targets — things a person can test, monitor, and in most cases meaningfully change. Risk factors divide into modifiable factors that can be treated or changed, and non-modifiable factors — age, sex, and genetic predisposition — that cannot be changed but inform how aggressively the modifiable ones should be addressed.
Major Risk Factors for Heart Disease — The Complete List
Modifiable major risk factors: high LDL cholesterol and atherogenic dyslipidemia; high blood pressure (hypertension); smoking and tobacco use; type 2 diabetes and insulin resistance; obesity (particularly central/abdominal adiposity); physical inactivity; unhealthy diet (high SFA, sodium, refined sugar; low fiber); excessive alcohol; chronic psychosocial stress; obstructive sleep apnea.
Non-modifiable risk factors: older age (significant increase after 45 in men, 55 in women); male sex (women have relative estrogen protection until menopause); family history of premature cardiovascular disease; genetic disorders including familial hypercholesterolemia and elevated Lp(a).
Emerging risk enhancers (ACC/AHA 2019): elevated Lp(a) ≥50 mg/dL; high-sensitivity CRP ≥2.0 mg/L; ApoB ≥130 mg/dL; ankle-brachial index below 0.9; chronic kidney disease; inflammatory conditions (RA, psoriasis, lupus).
High Blood Pressure — The Most Common Major Risk Factor
Hypertension is the single most common major cardiovascular risk factor in the United States, affecting approximately 119 million American adults — nearly half of all adults. Of those with hypertension, only about one in four has the condition adequately controlled. Blood pressure at rest should be below 120/80 mmHg; hypertension is defined as 130/80 mmHg or above (ACC/AHA 2017 definition). Stage 1 hypertension: 130–139/80–89 mmHg. Stage 2: 140/90 mmHg or above.
The mechanism of heart disease from hypertension is primarily mechanical: elevated pressure creates abnormal shear stress on the endothelium at arterial bends and bifurcations, initiating and accelerating atherosclerosis. Sustained hypertension also forces the left ventricle to work against increased resistance, causing left ventricular hypertrophy that can progress to heart failure. Hypertension is the “silent killer” — no symptoms until organ damage has occurred in the heart, brain, kidneys, or eyes.
High LDL Cholesterol — The Primary Driver of Plaque
LDL cholesterol is the primary substrate of atherosclerotic plaque formation, and its causal role in coronary artery disease is one of the most thoroughly established relationships in medicine. Approximately 94 million US adults have total cholesterol above 200 mg/dL. About 1 in 300 people have familial hypercholesterolemia (FH) — a genetic LDL receptor deficiency causing very high LDL from birth and premature heart attacks in the 30s and 40s without treatment. The clinical significance of any given LDL value depends on the person’s overall cardiovascular risk profile — this risk-stratified interpretation, not a universal cutoff, is the foundation of modern cholesterol management.
Smoking — A Major Risk Factor That Disappears With Cessation
Smokers have 2 to 4 times the coronary artery disease risk of non-smokers. Smoking causes approximately 20 percent of all US cardiovascular deaths. The mechanisms are multiple: nicotine-driven sympathetic activation raising heart rate and blood pressure; carbon monoxide reducing oxygen-carrying capacity (binding hemoglobin with 200 times the affinity of oxygen); oxidative compounds impairing endothelial nitric oxide production; and platelet activation increasing clot formation risk. Smoking is uniquely amenable to reversal — risk begins falling within hours of cessation and approaches non-smoker levels within 10 to 15 years. The risk multiplies dramatically when combined with other risk factors such as hypertension.
Type 2 Diabetes — A Cardiovascular Risk Equivalent
Adults with type 2 diabetes have 2 to 4 times the cardiovascular disease risk of non-diabetic adults. The ACC/AHA treat diabetes as a “cardiovascular risk equivalent” — adults with diabetes are managed for LDL and overall cardiovascular risk with similar intensity to those who have already had a heart attack. Mechanisms include hyperglycemia-driven advanced glycation end-products (AGEs) damaging the endothelium, atherogenic dyslipidemia from insulin resistance, autonomic neuropathy, and frequent coexisting hypertension and CKD. An estimated 96 million Americans have prediabetes — already producing atherogenic dyslipidemia and low-grade inflammation years before a formal diabetes diagnosis.
Obesity, Physical Inactivity, and Metabolic Syndrome
Obesity (BMI ≥30) affects approximately 42 percent of US adults, with 31 percent classified as overweight. Cardiovascular risk increases continuously with BMI above 25, though visceral fat distribution is a better predictor than BMI alone. Visceral adipose tissue secretes pro-inflammatory cytokines (IL-6, TNF-α, leptin) creating chronic systemic inflammation that accelerates atherosclerosis. Physical inactivity is an independent risk factor: ~25% of US adults meet neither exercise guideline, and sedentary behavior is associated with ~35% higher cardiovascular mortality. Regular aerobic exercise (150 minutes/week moderate intensity) reduces cardiovascular mortality by approximately 35 percent.
Metabolic syndrome — a cluster of abdominal obesity (waist >40 inches men, >35 inches women), elevated triglycerides (≥150 mg/dL), low HDL (<40 mg/dL men, <50 mg/dL women), elevated blood pressure (≥130/85 mmHg), and elevated fasting glucose (≥100 mg/dL) — requires three of five criteria for diagnosis. People with metabolic syndrome have 2 to 3 times the cardiovascular event risk of those without, even when each component is only mildly elevated, because the factors amplify each other through shared pathways of insulin resistance and systemic inflammation.
Non-Modifiable Risk Factors — Age, Sex, and Family History
Age: Clinically significant cardiovascular events become substantially more common after age 45 in men and 55 in women, reflecting decades of cumulative atherosclerosis exposure. Age is the primary driver of 10-year Pooled Cohort Equations risk scores and informs the urgency of addressing modifiable risk factors.
Sex: Estrogen has several cardioprotective effects — upregulating hepatic LDL receptors, improving endothelial function, and having anti-inflammatory properties. After menopause, estrogen withdrawal removes this protection and women’s cardiovascular event rates converge with men’s within 10 to 15 years. Women with premature menopause (before age 40) or a history of preeclampsia have accelerated cardiovascular risk beyond standard risk equations.
Family history: A first-degree relative with premature cardiovascular disease (MI/stroke before age 55 in a male relative, or before age 65 in a female relative) is an ACC/AHA 2019 risk enhancer that supports more aggressive treatment in borderline-risk patients. Family history reflects both shared genetic risk (polygenic LDL-raising variants, elevated Lp(a)) and shared environmental risk within families.
Emerging Risk Factors — Beyond the Standard List
Lp(a): A genetically determined lipoprotein elevated in ~20% of the population and not reducible by diet or standard statin therapy. Elevated Lp(a) ≥50 mg/dL is an independent cardiovascular risk factor and ACC/AHA 2019 risk enhancer. Measure at least once in adults with premature ASCVD or strong family history.
hsCRP: Elevated hsCRP (≥2.0 mg/L) reflects systemic inflammation and independently predicts cardiovascular events. The JUPITER trial confirmed patients with normal LDL but elevated CRP derived significant statin benefit — validating inflammation as a causal, not just associated, risk pathway.
Psychosocial stress: INTERHEART found psychosocial stress accounted for ~33% of global MI population-attributable risk — comparable to hypertension and larger than diabetes — through cortisol/sympathetic pathways and behavioral effects (stress → smoking, poor diet, inactivity, poor sleep).
How Risk Factors Combine — The Multiplicative Effect
Risk factors do not simply add — they multiply. A person with hypertension alone has approximately twice the cardiovascular risk of a normotensive person. Add hypercholesterolemia: roughly four times. Add smoking: eight to sixteen times. The Framingham Heart Study demonstrated this multiplicative interaction, and the Pooled Cohort Equations are built on the same framework.
The clinical implication: addressing two or three risk factors simultaneously produces proportionally much larger risk reduction than perfecting any single factor while ignoring the others. INTERHEART quantified this globally — nine modifiable factors explain 90% of MI risk worldwide, meaning the vast majority of heart disease is preventable.
For more on root causes, see what causes heart disease. For the distinction between changeable and non-changeable factors, see modifiable vs non-modifiable heart disease risks. For prevention strategies, see heart attack prevention, smoking and heart disease, and diabetes and heart disease.
Sources
American Heart Association — Know Your Risk Factors (heart.org) | Centers for Disease Control and Prevention — Heart Disease Risk Factors (cdc.gov) | National Heart, Lung, and Blood Institute — Heart Disease Risk Factors (nhlbi.nih.gov) | Yusuf S et al. (INTERHEART). Lancet 2004;364:937–52 | Grundy SM et al. 2018 AHA/ACC Cholesterol Guideline. JACC 2019;73(24):e285–e350
Understanding Absolute Risk vs. Relative Risk
When discussing cardiovascular risk factors, a critical distinction that affects how individuals and clinicians should respond to elevated risk markers is the difference between relative risk and absolute risk.
Relative risk describes how much more likely an event is compared to a reference person who lacks the risk factor. Saying that smokers have “2 to 4 times” the coronary artery disease risk of non-smokers is a statement of relative risk. It tells you the magnitude of the factor’s effect but not the actual probability of an event occurring in any given individual.
Absolute risk is the actual probability of experiencing a cardiovascular event within a defined time period — typically expressed as the 10-year risk of a fatal or non-fatal MI or stroke, as calculated by the Pooled Cohort Equations. Absolute risk determines whether treatment is likely to benefit the individual more than it burdens them.
Why the distinction matters in practice: A 35-year-old non-smoker who starts smoking doubles their relative cardiovascular risk. But if their baseline absolute 10-year risk was 1.5 percent, doubling it produces a risk of 3 percent — still very low in absolute terms. A 58-year-old with the same relative risk increase but a baseline 10-year risk of 18 percent would move to 36 percent — a dramatic and clinically urgent increase in absolute risk.
This is why age is such a powerful modifier of how seriously to take other risk factors. The same elevated LDL, the same hypertension, the same family history produces a much higher absolute risk in an older person simply because age itself has accumulated cardiovascular risk. Understanding this framework helps explain why guidelines recommend more aggressive treatment in older adults with risk factors and why “I’m only 35 — I don’t need to worry about this yet” is often incorrect thinking in the presence of multiple compounding risk factors.
Assessing Your Risk — How the Pooled Cohort Equations Work
The primary clinical tool for estimating 10-year cardiovascular risk in adults without established heart disease is the Pooled Cohort Equations (PCE), developed by the ACC/AHA and incorporated into their 2013 and updated 2019 cardiovascular prevention guidelines. Understanding what goes into the calculation helps explain why certain risk factors carry more weight in certain individuals.
The Pooled Cohort Equations use eight inputs:
- Age
- Sex
- Race (White or African American; the equations were derived from cohorts that included these two groups primarily)
- Total cholesterol (mg/dL)
- HDL cholesterol (mg/dL)
- Systolic blood pressure (mmHg)
- Blood pressure treatment status (yes/no)
- Diabetes status (yes/no)
- Current smoking status (yes/no)
The output is a 10-year risk percentage for the combined endpoint of fatal and non-fatal heart attack or stroke. Risk categories:
- Low risk: below 5% → lifestyle counseling, no medication generally needed
- Borderline risk: 5–7.4% → risk-benefit discussion; consider risk enhancers
- Intermediate risk: 7.5–19.9% → statin therapy discussion recommended when risk enhancers are present
- High risk: ≥20% → statin therapy recommended
The Pooled Cohort Equations have known limitations — they may overestimate risk in some populations, particularly those with already well-controlled risk factors, and underestimate risk in groups like South Asian adults. This is why the 2019 guidelines introduced “risk enhancers” — factors not captured by the PCE equations that can push a borderline-risk patient’s treatment decision toward medication. When the PCE result and the clinical picture remain uncertain, a coronary artery calcium score can serve as a tie-breaker: a CAC score of zero supports safely deferring medication; CAC above 100 or in the ≥75th percentile for age/sex supports initiating statin therapy.
How Individual Risk Factors Are Prioritized in Prevention
Not all risk factors deserve equal urgency in every patient. The prioritization of cardiovascular risk factor treatment should be guided by three principles:
1. Absolute risk magnitude: The higher the overall cardiovascular risk, the greater the absolute benefit of any risk factor reduction. A person with 25 percent 10-year risk benefits far more (in absolute events prevented) from each percentage point of risk reduction than a person with 4 percent 10-year risk. This means that in secondary prevention patients — those who have already had a heart attack or stroke — every modifiable risk factor should be aggressively treated, because the benefit of each treatment is very large in absolute terms.
2. Magnitude of the individual factor: A systolic blood pressure of 170 mmHg is a more urgent treatment priority than 132 mmHg, even though both are technically hypertensive. An LDL of 200 mg/dL requires more urgent attention than 140 mg/dL. The greater the deviation from the target, the greater the expected benefit of bringing it toward goal.
3. Modifiability: Among all risk factors, smoking cessation typically produces the largest individual risk reduction per dollar, per unit of effort, and per year of intervention — particularly because smoking interacts multiplicatively with other risk factors. Blood pressure control is also extremely cost-effective, particularly in people with Stage 2 hypertension (≥140/90 mmHg). LDL reduction through statin therapy provides large absolute risk reduction in high-risk groups at low cost using generic medications. These three — smoking cessation, blood pressure control, and LDL reduction — consistently produce the greatest absolute cardiovascular risk reduction across populations and represent the highest-priority targets in most patients.
Risk Factors Across a Lifetime — When They Matter Most
The cardiovascular impact of risk factor exposure is not uniform across the lifespan. The same risk factor experienced at different ages has different implications:
Childhood and adolescence (ages 5–20): Atherosclerosis begins early, with fatty streaks found in the aortas of children as young as 5 years old in autopsy studies. Childhood obesity, family history of premature cardiovascular disease, and early-onset hypertension or hyperlipidemia all predict adult cardiovascular risk. Universal cholesterol screening is now recommended at ages 9 to 11 and 17 to 21 specifically to detect familial hypercholesterolemia — the earlier FH is identified and treated, the more lifetime LDL exposure is reduced and the lower the cumulative plaque burden.
Young adulthood (ages 20–40): Risk factor accumulation in this period has long-term consequences that may not produce clinical events for decades. The CARDIA (Coronary Artery Risk Development in Young Adults) study demonstrated that risk factor burden in young adults predicts subclinical atherosclerosis measurable by coronary calcium scoring 25 years later. Young adults who smoke, have uncontrolled blood pressure, or have elevated LDL in their 20s and 30s are building plaque burden that will manifest as clinical events in their 50s and 60s.
Middle age (ages 40–65): The most critical intervention window. Cardiovascular events are becoming significantly more common in this decade, and the 10-year risk calculation becomes highly actionable. LDL-lowering, blood pressure control, diabetes management, and smoking cessation in this decade prevent a disproportionate share of cardiovascular events compared to the same interventions started at age 70.
Older adulthood (ages ≥65): Risk factor management remains beneficial even at older ages — the SPRINT trial showed blood pressure target reduction below 120 mmHg reduced cardiovascular events and mortality in adults averaging 68 years of age. Statin therapy reduces cardiovascular events in secondary prevention regardless of age. The absolute risk is highest in this age group, meaning the absolute benefit of each intervention is also highest — though individualized benefit-risk assessment becomes increasingly important as life expectancy shortens and polypharmacy concerns increase.
The Role of Cholesterol Beyond LDL — A Complete Lipid Picture
While LDL cholesterol is the primary lipid target in cardiovascular risk management, the complete lipid profile provides additional risk information that LDL alone does not capture:
Triglycerides are fats carried in VLDL particles, and elevated triglycerides (above 150 mg/dL) reflect both dietary excess (refined carbohydrates, alcohol) and underlying insulin resistance. VLDL remnants — the metabolic by-products of triglyceride-rich lipoprotein processing — are atherogenic in their own right, contributing to plaque formation independently of LDL. Very high triglycerides (above 500 mg/dL) additionally carry risk for acute pancreatitis, requiring urgent treatment.
HDL cholesterol facilitates reverse cholesterol transport — removing cholesterol from peripheral tissues and artery walls and returning it to the liver. Low HDL (below 40 mg/dL in men, below 50 mg/dL in women) is an independent cardiovascular risk factor. However, the clinical experience with HDL-raising drugs has been disappointing — torcetrapib, dalcetrapib, and niacin have all failed to reduce cardiovascular events when added to statin therapy despite substantially raising HDL. This suggests that HDL function (how well HDL particles actually transport cholesterol) matters more than HDL concentration, and that low HDL serves primarily as a marker of insulin resistance and metabolic dysfunction rather than as a direct treatment target.
Non-HDL cholesterol (total cholesterol minus HDL) captures all atherogenic lipoproteins — LDL plus VLDL plus IDL — in a single number. It is a more reliable predictor of cardiovascular risk than LDL alone in people with elevated triglycerides, where the Friedewald equation used to calculate LDL becomes inaccurate. The non-HDL target for high-risk patients is below 100 mg/dL (corresponding to LDL below 70 mg/dL).
Apolipoprotein B (ApoB) measures the total number of atherogenic particles — each LDL, VLDL, and IDL particle carries exactly one ApoB molecule. ApoB is increasingly recognized as a better predictor of cardiovascular risk than LDL cholesterol mass, particularly in insulin-resistant individuals where LDL particle number is often disproportionately elevated relative to LDL cholesterol. The ACC/AHA 2019 guidelines list ApoB ≥130 mg/dL as a risk enhancer that can support statin initiation in borderline-risk patients.
Sleep, Stress, and Environmental Risk Factors — Often Overlooked
Beyond the traditional major risk factors that appear on standard cardiovascular risk calculators, several additional factors substantially influence cardiovascular risk and deserve attention in a comprehensive risk assessment:
Obstructive sleep apnea (OSA): OSA affects an estimated 26 to 34 percent of middle-aged men and 17 to 28 percent of middle-aged women — and approximately 80 percent of those affected are undiagnosed. Each apneic episode during sleep triggers a hypoxic stress response: the brain signals the sympathetic nervous system to stimulate breathing, causing a surge in heart rate, blood pressure, and cortisol. These surges — occurring tens to hundreds of times per night in severe OSA — cause sustained elevation in daytime blood pressure and are the most common secondary cause of treatment-resistant hypertension. OSA is also associated with atrial fibrillation, nocturnal cardiac arrhythmias, and elevated cardiovascular event rates. CPAP therapy normalizes nighttime blood pressure surges, though its effects on daytime blood pressure and long-term cardiovascular events have been more modest in randomized trials than observational data suggested.
Chronic psychosocial stress: The INTERHEART study’s finding that psychosocial stress accounts for approximately 33 percent of global MI population-attributable risk is among the most striking findings in cardiovascular epidemiology. The biological pathways are well-characterized: chronic activation of the hypothalamic-pituitary-adrenal (HPA) axis elevates cortisol, which promotes visceral fat deposition, insulin resistance, and dyslipidemia. Chronic sympathetic nervous system activation elevates resting heart rate and blood pressure, increases platelet aggregation, and promotes endothelial dysfunction. The behavioral pathways are equally important: chronic stress is one of the strongest predictors of continued smoking, poor dietary choices, physical inactivity, and poor sleep — creating a cascade in which stress amplifies every other risk factor simultaneously.
Air pollution and environmental factors: Ambient fine particulate matter (PM2.5) from vehicle exhaust, industrial emissions, and wildfires penetrates deep into the lungs and triggers systemic inflammatory responses and oxidative stress that damage the endothelium. The Global Burden of Disease study estimated that ambient air pollution contributes to approximately 19 percent of cardiovascular deaths globally — making it a population-level risk factor of substantial magnitude, though largely outside individual control. In areas with poor air quality, indoor air filtration and limiting outdoor activity during high-pollution periods are practical risk-reduction measures.
Alcohol: The relationship between alcohol and cardiovascular risk is J-shaped in observational studies — low to moderate alcohol consumption (1–2 drinks per day) is associated with lower cardiovascular risk compared to abstinence or heavy drinking. However, this observational association has been questioned by Mendelian randomization studies suggesting the benefit may reflect confounding rather than a causal protective effect. Heavy alcohol consumption (>3 drinks/day consistently) is clearly harmful: it raises blood pressure, promotes atrial fibrillation, causes alcoholic cardiomyopathy, and raises triglycerides significantly. Current ACC/AHA guidance does not recommend alcohol for cardiovascular benefit; the population-level risk from heavy drinking and alcohol use disorder substantially outweighs any potential benefit from moderate use.
Together, these risk factors — traditional and emerging, biological and behavioral, modifiable and non-modifiable — form a comprehensive picture of what determines an individual’s cardiovascular trajectory. The most effective cardiovascular prevention addresses as many of these simultaneously as possible, recognizing that each factor addressed reduces the amplifying effect on all others.